Resources

Brainomix, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).

Engitix announced the appointment of Ryan Richardson to its Board of Directors as Independent Non-Executive Director (NED).

Discovery Park welcomed two climate-tech companies to its innovation campus

o2h Technology Launches Tech Kickstarter 5.0 to Support Early-Stage Startups

Alliance of CGT Manufacturing Partners (ACGMP) founding members aim to help cell and gene therapy developers find manufacturing partners across regions and modalities, with a shared focus on global patient access.

ELRIG announced the keynote speakers for Protein Sciences in Drug Discovery 2026.

Coulter Partners successfully led a search assignment for Valo Therapeutics Group to place Carlos de Sousa, M.D., MBA, as Chief Executive Officer.

Poolbeg Pharma announces that a South Korean patent relating to POLB 001 has been formally granted.

Cancer Research UK have signed an agreement with ORIC Pharmaceuticals, Inc. to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development.

Aravax announces it will be communicating topline results from its Phase 2 study of its lead product, PVX108 for the treatment of peanut allergy, at major conferences in the US and Europe in November 2026

The Cell and Gene Therapy (CGT) Catapult has published new insights into the advancement of the UK’s cell and gene therapy industry in its Annual Review.

Brainomix announced new data published in the esteemed American Journal of Respiratory & Critical Care Medicine (AJRCCM)

Medicines Discovery Catapult has appointed Dr Mike Strange as its Chief Executive Officer.

Poolbeg Pharma announces its unaudited interim results for the six months to 30 June 2026.

Poolbeg Pharma reaffirmed that participant recruitment for the POLB 001 TOPICAL trial is progressing well. Following the previously announced six-patient safety cohort, a total of eight participants have now been dosed out of c.30, since the first patient dosed in July 2026.

Global drug development consultancy Boyds has strengthened its Regulatory Affairs team with the appointment of two senior specialists.

To mark World Cancer Research Day, we are proud to share this film celebrating innovation in immunotherapy, the passion of our team working together in scientific discovery and our shared goal of developing new approaches for patients with cancer.

Barry Callebaut, the world’s leading manufacturer of high-quality chocolate and cocoa solutions, has moved into Colworth Science Park’s food tech incubator Gastronomica.

Latest Press Release Announcing Momentum Pharma (BIA member organisation) growth, launching a business in Australia to better serve the Australia and APAC region.

Positive interim review marks key milestone for POLB 001 clinical development